Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by vikinggaleon May 31, 2023 10:18am
580 Views
Post# 35472307

Summary of Concerns at Spectral Medical inc.

Summary of Concerns at Spectral Medical inc.
Spectral Medical Inc.
Notice to ALL Shareholders
Annual General & Special Meeting of The Shareholders of
 Spectral Medical Inc. to be held:
 June 7, 2023, at 4 pm Toronto time.
Your Online Vote Must be in by June 4, 2023, 11:59 pm EDT
If You Have Voted Online and You Want to CHANGE Your Vote, You Are Able to Change your Vote Online,
 IT MUST BE Changed
BEFORE June 4, 2023, 11.59 pm EDT
 
 
Summary of Critical Concerns at Spectral Medical Inc.
 
This is a brief summary of my previous deep dive post, I addressed critical concerns at Spectral Medical Inc. Shareholders must act swiftly to address the alarming decline in market capitalization, falling share prices, and questionable compensation practices.
 
1.   Alarming Market Decline: Under CEO Chris Seto, Spectral Medical Inc. has experienced a significant drop in market capitalization and share prices, raising doubts about effective leadership.
2.   Questionable Compensation: Despite the company's value plunging, CEO Chris Seto received substantial compensation, while additional stock incentives were granted to the board and executives, suggesting a misalignment with shareholder interests.
3.   Neglected Shareholder Concerns: Limited accessibility for American investors and a lack of shareholder dialogue further contribute to concerns surrounding Spectral Medical Inc.
4.   The disparity in Returns: Shareholders have not seen returns on their investments, while the board and management continue to receive substantial compensation and stock incentives.
5.   Failing Duty to Shareholders: The board of directors has failed to effectively represent shareholder interests, warranting a vote to WITHHOLD support for each director.
 
Conclusion: Immediate action is essential to address critical issues at Spectral Medical Inc. Shareholders must exercise their voting rights to remove current directors and demand leadership that prioritizes shareholder value. Time is of the essence to protect the intrinsic value of shareholders' investments.
 
I will WITHHOLD my vote for the re-election of ALL Directors

Key Takeaway’s
1.   Spectral Medical Inc.'s value has plummeted by over 58% under CEO Chris Seto's leadership.
2.   The Board and Management prioritize their own compensation over the interests of shareholders.
3.   Shareholders have been neglected by the current leadership at Spectral Medical Inc.
4.   Despite the potential impact of the company's technology on global sepsis cases, the story remains untold, and U.S. investors face difficulties in participating due to the lack of a U.S. listing.
5.   It is crucial to vote to WITHHOLD the re-election of the directors if you are dissatisfied with the current leadership.
6.   Share this information with fellow shareholders to raise awareness.
 
Always invest only that which you can afford to lose. Always seek professional investment advice when making decisions about your investments. At ALL times Do Your Own Research on your investments.
<< Previous
Bullboard Posts
Next >>